Former Juniper exec joins 2X Oncology as CEO

Market Intelligence

WORKFLOW SOLUTIONS
PRODUCTS
See More S&P Global Solutions
CONTENT
PODCASTS
SEE ALL EPISODES
SECTOR-SPECIFIC INSIGHTS
More ways we can help
NEWS & RESEARCH TOPICS
See More
Featured Events
In Person8th Annual European Perspectives Seminar: The Big Picture
- 09/26/2024
- The Charles Hotel Sophienstraße 28 München, 80333
- 10:00 -17:00 CEST
Insurance IN/sights Symposium 2024
The Insurance IN/sights Symposium, formerly known as the Insurance M&A Symposium, is a place where attendees can hear and learn from experts on pressing topics to best leverage data sources and walk away with tangible solutions.
In PersonInteract New York 2024
- 10/15/2024
- Center415, 415 5th Avenue, New York, NY
- 10:00 -17:00 CEST
PLATFORMS
OTHER PRODUCTS
See All Product Logins

In This List

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

30 May, 2017 | 18:55

Author Imran Khushal
Theme Healthcare & Pharmaceuticals

2X Oncology Inc. named George Elston as CEO and a board member.

Elston was previously CFO of Juniper Pharmaceuticals Inc.

2X Oncology is a clinical stage company developing targeted therapeutics that leverage proprietary drug response predictor companion diagnostic technology to address unmet needs in women's cancer.